Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21686845 | 0.85 | GABRP (0.50) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL30672840 | 0.85 | GABRP (0.50) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL25427912 | 0.82 | IMPDH2 (0.39) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL12941910 | 0.80 | TYRO3 (0.50) | KDM4EALDH1A1HPGDSMN1; SMN2TYRO3 | |
| SCHEMBL16964686 | 0.77 | DAO (0.50) | KDM4EALDH1A1HPGDSMN1; SMN2TYRO3 | |
| SCHEMBL3265232 | 0.73 | LCK (0.42) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL23234575 | 0.72 | GRIN2D (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2CHEK1 | |
| SCHEMBL3669922 | 0.72 | GRIN2D (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL14828969 | 0.70 | KDM4E (0.45) | KDM4EALDH1A1PARP1TYRO3DYRK1B | |
| SCHEMBL4950563 | 0.70 | PARP1 (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116472047-B | Arylamine derivative, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-119060049-A | Pyridopyrimidine derivatives serving as small GTPase KRAS mutation inhibitors | 思路迪生物医药(上海)有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118215663-A | Pyridopyrimidine derivatives serving as small GTPase KRAS mutation inhibitors | 思路迪生物医药(上海)有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-116472047-A | Arylamine derivative, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023098832-A1 | PYRIDOPYRIMIDINE DERIVATIVES SERVING AS SMALL GTP ENZYME KRAS MUTATION INHIBITORS | 思路迪生物医药(上海)有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023098832-A1 | PYRIDOPYRIMIDINE DERIVATIVES SERVING AS SMALL GTP ENZYME KRAS MUTATION INHIBITORS | 思路迪生物医药(上海)有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-116217591-A | Pyridopyrimidine derivatives serving as KRAS G12D mutation inhibitors | 思路迪生物医药(上海)有限公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2023078241-A1 | AROMATIC AMINE DERIVATIVES AND PREPARATION METHOD AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078241-A1 | AROMATIC AMINE DERIVATIVES AND PREPARATION METHOD AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | KDM4E 3689/4885ALDH1A1 3370/4885HPGD 1741/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KDM4E 3689/4885ALDH1A1 3370/4885HPGD 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.